Exploring Ketamine for Older Adults: A Groundbreaking Pilot Study (Lenze, ClinicalTrials.gov, 2020)
Introduction: In 2020, Dr. Eric Lenze and his team launched a pilot study to explore how ketamine might help older […]
Patient Regulation
Patient Regulation
Esketamine: A Groundbreaking Antidepressant Explained (Kim et al., NEJM, 2019)
Introduction: In 2019, a team of experts published an article in The New England Journal of Medicine highlighting the significance
Esketamine: A Fast-Acting Treatment for Depression, Explained (Hough, FDA, 2019)
Introduction: In 2019, the FDA approved esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). This report by
Esketamine: A New Hope for Treatment-Resistant Depression (FDA Advisory Committees, 2019)
Introduction: The FDA reviewed a new treatment called esketamine, a nasal spray developed for people with treatment-resistant depression (TRD). TRD
Ketamine and Esketamine for Depression: Promising Hope for Tough Cases (Duke Scholars, January 2023)
Introduction: Ketamine and esketamine have been explored in medical research for treating treatment-resistant depression (TRD), a severe form of depression
How Drugs Get Approved: What the FDA Does and Why It Matters to You (FDA, 2019)
Introduction: The U.S. Food and Drug Administration (FDA) plays a crucial role in ensuring the safety and effectiveness of medications.
New Hope for Mental Health: Ketamine and Esketamine Research Trends, Oct 2024
Introduction A recent study by Vekhova, Namiot, Jonsson, and Schiöth (Oct 2024) explores the growing use of ketamine and esketamine